Truist Securities Maintains Buy on Treace Medical Concepts, Lowers Price Target to $12-Report released on 9th Nov 2023
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has maintained a Buy rating on Treace Medical Concepts (NASDAQ:TMCI) but lowered the price target from $17 to $12.
November 10, 2023 | 2:53 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Truist Securities maintains a Buy rating on Treace Medical Concepts but reduces the price target from $17 to $12.
The reduction in price target by Truist Securities, despite maintaining a Buy rating, could lead to a negative short term sentiment among investors, potentially causing a decrease in TMCI's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100